GSK Halts Two Mid-Stage Studies of ICOS AgonistClinical Trials, GlaxoSmithKline, Head & Neck Squamous Cell Carcinoma (HNSCC), Independent Data Monitoring Committee (IDMC), Inducible T cell co-stimulatory (ICOS) agonist, Keytruda, Merck, Oncology, PD-1/PD-L1 inhibitors, R&DGlaxoSmithKline halted two mid-stage studies assessing feladilimab combined with Merck’s Keytruda as a potential treatment in different oncology settings. Read more April 15, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/04/GSK-Halts-Two-Mid-Stage-Studies-of-ICOS-Agonist-Feladilimab-BioSpace-4-15-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-04-15 12:18:592021-04-15 12:33:07GSK Halts Two Mid-Stage Studies of ICOS Agonist